EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Asmita Khaniya iD, S M Ali Hossieni Rad, Josh Halpin, Supannikar Tawinwung iD, Alexander McLellan, Koramit Suppipat iD, Nattiya Hirankarn

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2023-008555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Asmita Khaniya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Microbiology, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antigens, CD19, Antigens, CD20, Receptors, Chimeric Antigen, DNA Transposable Elements. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HRC Explorer, National Research Council of Thailand, Royal Society NZ Marsden Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.

Methods

We developed a second-generation CAR directing CD19 and CD20 antigens, incorporating them in a head-to-head orientation from a bidirectional promoter using a single Sleeping Beauty transposon system. The efficacy of bidirectional promoter-driven dual CD19 and CD20 CAR T cells was determined in vitro against cell lines expressing either, or both, CD19 and CD20 antigens. In vivo antitumor activity was tested in Raji lymphoma-bearing immunodeficient NOD-scid IL2Rgamma null (NSG) mice.

Results

Of all tested promoters, the bidirectional EF-1 α promoter optimally expressed transcripts from both sense (CD19-CAR) and antisense (GFP.CD20-CAR) directions. Superior cytotoxicity, cytokine production and antigen-specific activation were observed in vitro in the bidirectional EF-1 α promoter-driven CD19/CD20 CAR T cells. In contrast, a unidirectional construct driven by the EF-1 α promoter, but using self-cleaving peptide-linked CD19 and CD20 CARs, showed inferior expression and in vitro function. Treatment of mice bearing advanced Raji lymphomas with bidirectional EF-1 α promoter-driven CD19/CD20 CAR T cells effectively controlled tumor growth and extended the survival of mice compared with group treated with single antigen targeted CAR T cells.

Conclusion

The use of bidirectional promoters in a single vector offers advantages of size and robust CAR expression with the potential to expand use in other forms of gene therapies like CAR T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Antigens, CD20Receptors, Chimeric AntigenDNA Transposable ElementsPromoter Regions, GeneticImmunotherapy, AdoptiveHumansAnimalsMiceMice, Inbred NODCell Line, TumorMice, SCIDXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Cell EngineeringHematologic NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric Antigen

Substanzen

Antigens, CD19Antigens, CD20Receptors, Chimeric AntigenDNA Transposable Elements

Autor:innen und Institutionen

  • Medical Microbiology, Chulalongkorn University, Bangkok, Thailand.
  • Cellular Immunotherapy Research Unit, Chulalongkorn University, Bangkok, Thailand.
  • Kite Pharma Inc, Santa Monica, California, USA.
  • Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.
  • Pharmacology and Physiology, Chulalongkorn University Faculty of Pharmaceutical Sciences, Bangkok, Thailand.
  • Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand koramit.s@chula.ac.th Nattiya.h@chula.ac.th alex.mclellan@otago.ac.nz.

ORCID-Profile: Asmita Khaniya, Supannikar Tawinwung, Koramit Suppipat

Förderung

  • HRC Explorer
  • National Research Council of Thailand
  • Royal Society NZ Marsden Fund
  • Program Management Unit for Human Resource & Institutional Development

Zitieren

APA

Khaniya, A., Rad, S. M. A. H., Halpin, J., Tawinwung, S., McLellan, A., Suppipat, K., & Hirankarn, N. (2024). Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008555

Vancouver

Khaniya A, Rad SMAH, Halpin J, Tawinwung S, McLellan A, Suppipat K, et al. Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008555

BibTeX
@article{Khaniya2024,
  author = {Khaniya, Asmita and Rad, S M Ali Hossieni and Halpin, Josh and Tawinwung, Supannikar and McLellan, Alexander and Suppipat, Koramit and Hirankarn, Nattiya},
  title = {Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2023-008555}
}
Kostenlos starten →